Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   39219   clinical trials with a EudraCT protocol, of which   6426   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-001551-31
    Sponsor's Protocol Code Number:BGB-3111-304
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2017-11-02
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-001551-31
    A.3Full title of the trial
    An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Estudio de fase III, internacional, abierto y aleatorizado de BGB-3111 en comparación con bendamustina más rituximab, en pacientes con leucemia linfocítica crónica o linfoma linfocítico de células pequeñas no tratados previamente
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Estudio en fase III de BGB-3111 en comparación con bendamustina más rituximab, en pacientes con leucemia linfocítica crónica o linfoma linfocítico de células pequeñas no tratados previamente
    A.4.1Sponsor's protocol code numberBGB-3111-304
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBeiGene, Ltd.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBeiGene, Ltd.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBeiGene, Ltd.
    B.5.2Functional name of contact pointUS
    B.5.3 Address:
    B.5.3.1Street AddressUS
    B.5.3.2Town/ cityUS
    B.5.3.3Post codeUS
    B.5.3.4CountryUnited States
    B.5.4Telephone number+34900 811 335
    B.5.6E-mailpraregulatoryaffairs@prahs.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBGB-3111
    D.3.2Product code BGB-3111
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNnot yet established
    D.3.9.1CAS number 1691249-45-2
    D.3.9.2Current sponsor codeBGB-3111
    D.3.9.4EV Substance CodeSUB184615
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number80
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Levact
    D.2.1.1.2Name of the Marketing Authorisation holderAstellas Pharma GmBH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBendamustine
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBENDAMUSTINE HYDROCHLORIDE
    D.3.9.1CAS number 3543-75-7
    D.3.9.4EV Substance CodeSUB00696MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name MabThera
    D.2.1.1.2Name of the Marketing Authorisation holderRoche Registration Ltd
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRituximab
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNRITUXIMAB
    D.3.9.1CAS number 174722-31-7
    D.3.9.4EV Substance CodeSUB12570MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas no tratados previamente.
    E.1.1.1Medical condition in easily understood language
    Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10003946
    E.1.2Term B-Lymphocytic, CLL (Kiel Classification)
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10041152
    E.1.2Term Small lymphocytic lymphoma, consistent with CLL (Working Formulation)
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare efficacy between treatment groups in cohort 1, as measured by progression-free survival determined by independent central review
    Comparar la eficacia entre grupos de tratamiento en la cohorte 1 con respecto a la supervivencia sin progresión determinada mediante revisión central independiente.
    E.2.2Secondary objectives of the trial
    To evaluate efficacy in cohort 1, as measured by the following:
    o Overall response rate determined by independent central review and by investigator assessment
    o Overall survival
    o Duration of response determined by independent central review and by investigator assessment
    o Progression-free survival determined by investigator assessment
    o Patient-reported outcomes
    • To evaluate efficacy in cohort 2 (patients with del[17p]), as measured by the following:
    o Overall response rate determined by independent central review
    o Overall survival
    o Progression-free survival determined by independent central review
    o Duration of response determined by independent central review
    • To compare safety between the treatment groups in cohort 1
    • To evaluate pharmacokinetics of BGB-3111
    • Evaluar la eficacia en la cohorte 1 con respecto a lo siguiente:
    o Tasa de respuesta global conforme a la revisión central independiente y a la evaluación del investigador.
    o Supervivencia global.
    o Duración de la respuesta conforme a la revisión central independiente y a la evaluación del investigador.
    o Supervivencia sin progresión conforme a la evaluación del investigador.
    o Resultados notificados por el paciente.
    • Evaluar la eficacia en la cohorte 2 (pacientes con la del[17p]), con respecto a lo siguiente:
    o Tasa de respuesta global conforme a la revisión central independiente.
    o Supervivencia global.
    o Supervivencia sin progresión conforme a la revisión central independiente.
    o Duración de la respuesta conforme a la revisión central independiente.
    • Comparar la seguridad entre los grupos de tratamiento en la cohorte 1.
    • Evaluar la farmacocinética de BGB-3111.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Unsuitable for chemoimmunotherapy with FCR in the opinion of the investigator
    2. Confirmed diagnosis of CD20-positive CLL or SLL that meets the CLL criteria (Hallek et al, 2008)
    3. Binet Stage C disease, or Binet Stage B or A disease requiring treatment as defined by at least one of the criteria (Hallek et al, 2008)
    4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
    5. Life expectancy ≥ 6 months
    6. Adequate bone marrow function
    7. Patient must have adequate organ function
    8. Female patients of childbearing potential must practice highly effective methods of contraception initiated prior to first dose of study drug, for the duration of the study, and for ≥ 90 days after the last dose of BGB-3111, 3 months after the last dose of bendamustine, or 12 months after the last dose of rituximab, whichever is longer.
    9. Male patients are eligible if vasectomized or if they agree to the use of barrier contraception with other methods described above during the study treatment period and for ≥ 90 days after the last dose of BGB-3111 or 3 months after the last dose of bendamustine whichever is longer.
    10. Ability to provide written informed consent and can understand and comply with the requirements of the study
    1. No ser aptos para recibir quimioinmunoterapia con FCR en opinión del investigador
    2. Diagnóstico confirmado de LLC o LLCP CD20+ de acuerdo con los criterios del LLC (Hallek et al., 2008)
    3. Enfermedad en estadio C de Binet o enfermedad en estadios A o B de Binet, que requieren tratamiento por cumplirse al menos uno de los criterios (Hallek et al., 2008)
    4. Estado funcional del Grupo Oncológico Cooperativo del Este (ECOG) de 0, 1 o 2
    5. Esperanza de vida ≥6 meses
    6. Función de la médula ósea adecuada
    7. Los pacientes deben tener una función orgánica adecuada
    8. Las mujeres en edad fértil deben utilizar métodos anticonceptivos muy eficaces desde antes de la primera dosis del fármaco del estudio, durante todo el estudio y en un plazo ≥90 días tras la última dosis de BGB-3111, 3 meses tras la última dosis de bendamustina o 12 meses tras la última dosis de rituximab, lo que suponga más tiempo
    9. Los pacientes varones son aptos si tienen hecha una vasectomía o aceptan el uso de anticonceptivos de barrera junto con otros de los métodos descritos anteriormente durante el período de tratamiento del estudio y en un plazo ≥90 días tras la última dosis de BGB-3111 o 3 meses tras la última dosis de bendamustina, lo que suponga más tiempo
    10. Capacidad de proporcionar el consentimiento informado por escrito y de entender y cumplir los requisitos del estudio
    E.4Principal exclusion criteria
    1. Previous systemic treatment for CLL/SLL
    2. Known prolymphocytic leukemia or history of, or currently suspected, Richter’s transformation
    3. Clinically significant cardiovascular disease
    4. Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast
    5. History of severe bleeding disorder
    6. History of stroke or intracranial hemorrhage within 6 months before first dose of study drug
    7. Severe or debilitating pulmonary disease
    8. Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
    9. Active fungal, bacterial and/or viral infection requiring systemic therapy
    10. Known central nervous system involvement by leukemia or lymphoma
    11. Underlying medical conditions that, in the investigator’s opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or AEs
    12. Known infection with HIV, or serologic status reflecting active hepatitis B or C infection
    13. Major surgery within 4 weeks of the first dose of study drug
    14. Pregnant or lactating women
    15. Vaccination with a live vaccine within 35 days prior to the first dose of study drug
    16. Ongoing alcohol or drug addiction
    17. Hypersensitivity to BGB-3111, bendamustine, or rituximab or any of the other ingredients of the study drugs
    18. Requires ongoing treatment with a strong CYP3A inhibitor or inducer
    19. Concurrent participation in another therapeutic clinical trial.
    E.4 CRITERIOS PRINCIPALES DE EXCLUSIÓN
    1. Tratamiento sistémico previo para la LLC/LLCP
    2. Leucemia prolinfocítica conocida o transformación de Richter pasada, presunta o en curso
    3. Enfermedad cardiovascular de importancia clínica
    4. Neoplasia maligna en los 3 años anteriores, excepto carcinoma basocelular o espinocelular, cáncer superficial de vejiga o carcinoma in situ del cuello uterino o de la mama tratados con intención curativa
    5. Antecedentes de trastornos hemorrágicos graves
    6. Antecedentes de accidente cerebrovascular o hemorragia intracraneal en los 6 meses previos a la primera dosis del fármaco del estudio
    7. Neumopatía grave o debilitante
    8. Incapacidad para tragar las cápsulas o enfermedad que afecte de forma significativa al funcionamiento gastrointestinal, por ejemplo, síndrome de malabsorción, resección gástrica o del intestino delgado, intervenciones de cirugía bariátrica, enfermedad inflamatoria intestinal sintomática u obstrucción intestinal parcial o total
    9. Infecciones micóticas, bacterianas y/o virales activas que requieran tratamiento sistémico
    10. Afectación conocida del sistema nervioso central por la leucemia o el linfoma
    11. Enfermedades subyacentes que, en opinión del investigador, hagan que la administración del fármaco del estudio sea peligrosa u oculte la interpretación de la toxicidad o los AA
    12. Infección conocida por el VIH o estado serológico que refleja una infección activa por el virus de la hepatitis B o C
    13. Intervención de cirugía mayor en las 4 semanas previas a la primera dosis del fármaco del estudio
    14. Mujeres embarazadas o en período de lactancia
    15. Administración de una vacuna con microbios vivos en los 35 días previos a la primera dosis del fármaco del estudio
    16. Alcoholismo o drogadicción en curso
    17. Hipersensibilidad a BGB-3111, bendamustina, rituximab o a cualquiera de los demás componentes de los fármacos del estudio
    18. Necesidad de tratamiento con un inhibidor o inductor potente de CYP3A
    19. Participación simultánea en otro ensayo clínico terapéutico
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is progression-free survival in cohort 1 (patients without del[17p]) determined by independent central review using the iwCLL guidelines with modification for treatment-related lymphocytosis, and defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurs first.
    El criterio de valoración principal es la supervivencia sin progresión en la cohorte 1 (pacientes sin del[17p]) conforme a la revisión central independiente utilizando las directrices del Grupo de trabajo internacional sobre leucemia linfocítica crónica (iwCLL) con modificación para la linfocitosis relacionada con el tratamiento, y definida como el tiempo desde la aleatorización hasta la fecha de la primera documentación de la progresión de la enfermedad o la muerte, lo que ocurra primero.
    E.5.1.1Timepoint(s) of evaluation of this end point
    1 interim analysis of progression-free survival by independent central review in cohort 1, performed when approximately 79 events (67% of the target number of events at final analysis) from the arms A and B are observed. It is estimated that it will take approximately 25 months to observe 79 events. The final analysis of progression-free survival will take place after 118 events are observed, which is estimated as approximately 35 months from study start.
    En la cohorte 1, se llevará a cabo un análisis intermedio de la supervivencia sin progresión, determinada mediante revisión central independiente, cuando se hayan observado aproximadamente 79 casos de supervivencia sin progresión (67 % del número objetivo de casos en el análisis final) en los grupos A y B. Se calcula que se necesitarán aproximadamente 25 meses para observar 79 casos. El análisis final de la supervivencia sin progresión se llevará a cabo una vez que se hayan observado 118 casos, lo cual se calcula que sucederá aproximadamente 35 meses después del inicio del estudio.
    E.5.2Secondary end point(s)
    • Overall response rate in cohort 1 defined as the proportion of patients who achieve a complete response, complete response with incomplete bone marrow recovery, partial response, or partial response with lymphocytosis, determined by independent central review and by investigator assessment
    • Overall survival in cohort 1 defined as the time from randomization to the date of death due to any reason
    • Duration of response in cohort 1 determined by independent central review and by investigator assessment using the iwCLL criteria with modification for treatment-related lymphocytosis, and defined as the time from the date that response criteria are first met to the date that disease progression is objectively documented or death, whichever occurs first
    • Progression-free survival in cohort 1 determined by investigator assessment
    • Patient-reported outcomes in cohort 1 measured by the EQ-5D-5L and EORTC QLQ-C30 questionnaires
    • Overall response rate in cohort 2 (patients with del[17p]) determined by independent central review
    • Overall survival in cohort 2
    • Progression-free survival in cohort 2 determined by independent central review
    • Duration of response in cohort 2 determined by independent central review
    • Safety parameters, including AEs, SAEs, clinical laboratory tests, physical exams, and vital signs
    • Pharmacokinetic parameters such as apparent clearance of the drug from plasma (CL/F) and AUC0-12
    • Tasa de respuesta global en la cohorte 1 definida como la proporción de pacientes que logran una respuesta completa, respuesta completa con recuperación medular incompleta, respuesta parcial o respuesta parcial con linfocitosis, conforme a la revisión central independiente y a la evaluación del investigador
    • Supervivencia general en la cohorte 1 definida como el tiempo desde la aleatorización hasta la fecha de la muerte debida a cualquier motivo
    • Duración de la respuesta en la cohorte 1 conforme a la revisión central independiente y a la evaluación del investigador usando los criterios del iwCLL con modificación para la linfocitosis relacionada con el tratamiento, y definida como el tiempo desde el momento en que se cumplen por primera vez los criterios de respuesta hasta la fecha en la que se documenta objetivamente por primera vez la progresión de la enfermedad o la muerte, lo que ocurra primero
    • Supervivencia sin progresión en la cohorte 1 conforme a la evaluación del investigador
    • Resultados comunicados por el paciente en la cohorte 1 medidos por los cuestionarios EQ-5D-5L y QLQ-C30 de la EORTC
    • Tasa de respuesta global en la cohorte 2 (pacientes con del[17p]) conforme a la revisión central independiente
    • Supervivencia general en la cohorte 2
    • Supervivencia sin progresión en la cohorte 2 conforme a la revisión central independiente
    • Duración de la respuesta en la cohorte 2 conforme a la revisión central independiente
    • Parámetros de seguridad, incluidos los AA, AAG, análisis clínicos, exploraciones físicas y constantes vitales
    • Parámetros farmacocinéticos como el aclaramiento plasmático aparente del fármaco (CL/F) y el ABC0-12
    E.5.2.1Timepoint(s) of evaluation of this end point
    At time of interim analysis if the PFS comparison between the 2 arms in cohort 1 crosses the stopping boundary. Or at the time of final PFS analysis.
    En el momento del análisis provisional, si la comparación de la SSP entre los 2 grupos de la cohorte 1 cruza el límite de detención. O en el momento del análisis final de la SSP.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA90
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Austria
    Belgium
    Canada
    Czech Republic
    France
    Germany
    Hungary
    Israel
    Italy
    Korea, Republic of
    New Zealand
    Poland
    Russian Federation
    Spain
    Sweden
    Taiwan
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    La última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 93
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 374
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state33
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 250
    F.4.2.2In the whole clinical trial 467
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients receiving BGB-3111, who in the opinion of the investigator, continue to benefit from study treatment may continue treatment with BGB-3111 by enrolling on the BGB-3111 Long Term Extension Study.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-12-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-12-26
    P. End of Trial
    P.End of Trial StatusOngoing
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA